Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

A self-deactivating cytokine platform technology

Obiettivo

Adoptive cell therapies harness the power of our immune system to treat and even cure severe diseases from cancer via infections to autoimmunity. These emerging therapies use engineered lymphocytes to fight disease-causing cells in patients and major progress has been achieved in the treatment of blood cancers. In contrast, solid tumors remain notoriously difficult to treat with adoptive cell therapies. Very often, this is due to the strongly immunosuppressive microenvironment of solid cancers, limiting the effectiveness of cell therapies.

Cytokines with their potent immunoregulatory functions can alleviate these challenges. A paradigm for this is interleukin 12 (IL-12). IL-12 has strong immune-activating properties, increases antigen presentation, and inhibits or reprograms otherwise immunosuppressive cells in the tumor microenvironment. Despite this ideal signature, IL-12 has fallen short of its promises in the clinics – mainly due to dose-limiting toxicity. Maintaining a maximum IL-12 concentration at desired sites of action while concurrently keeping the systemic level low is thus a major dilemma when it comes to using IL-12 in the clinics.

We have developed a self-deactivating IL-12 that is only active at the site of production and release, e.g. from CAR T cells. As such, it makes the desired properties of IL-12 available at relevant sites while avoiding systemic effects. Building on strong preliminary data and a team with complementary expertise, this project will i) provide in vivo Proof of Concept data ii) secure the IP for the locally active IL-12 and iii) take major steps towards commercialization of the technology.

Our platform technology will make adoptive cell therapies for solid tumors more effective while maintaining their safety. Further applications lie in virus- and nucleic acid-based therapeutic approaches thus making this technology highly attractive to companies developing different modalities in the space of next generation immunotherapy.

Campo scientifico (EuroSciVoc)

Questo progetto non è ancora stato classificato con EuroSciVoc.
Suggerisci i campi scientifici che ritieni più rilevanti e aiutaci a migliorare il nostro servizio di classificazione.

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) ERC-2026-POC

Vedi tutti i progetti finanziati nell’ambito del bando

Istituzione ospitante

TECHNISCHE UNIVERSITAET MUENCHEN
Contributo netto dell'UE
€ 150 000,00
Indirizzo
Arcisstrasse 21
80333 Muenchen
Germania
Regione
Bayern Oberbayern München, Kreisfreie Stadt
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
Nessun dato

Beneficiari (1)